A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Clarissa G. Barnes, Frederick L. Brancati, MD, MHS, and Tiffany L. Gary, PhD, MHS
To combat the rising incidence of type 2 diabetes, New York City requires laboratories with electronic reporting capacity to upload data on hemoglobin A1c measurements to a city department of health registry.
Clinicians in Catholic health care institutions cannot prescribe contraceptives for pregnancy prevention under a false diagnosis without committing fraud and contravening doctrine. Referrals are one option the authors consider for navigating patient requests for contraception.
AMA J Ethics. 2018;20(7):E630-636. doi:
10.1001/amajethics.2018.630.
Cynthia E. Schairer, PhD, Caryn Kseniya Rubanovich, MS, and Cinnamon S. Bloss, PhD
Questions about data privacy need to be addressed when research institutions negotiate with companies developing mobile health applications. Commercial terms of use and data sharing notifications should be reviewed before use in human subject research settings.
AMA J Ethics. 2018;20(9):E864-872. doi:
10.1001/amajethics.2018.864.